Related references
Note: Only part of the references are listed.Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
Recently targeted kinases and their inhibitors - the path to clinical trials
Stefan Knapp et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri et al.
NATURE CHEMICAL BIOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD
Melissa V. Gammons et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2013)
Targeting Diverse Signaling Interaction Sites Allows the Rapid Generation of Bivalent Kinase Inhibitors
Zachary B. Hill et al.
ACS CHEMICAL BIOLOGY (2012)
Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)
Jeffrey M. Axten et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor
Solveigh C. Koeberle et al.
NATURE CHEMICAL BIOLOGY (2012)
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
Jingsong Yang et al.
CHEMISTRY & BIOLOGY (2011)
Understanding the Impact of the P-loop Conformation on Kinase Selectivity
Cristiano R. W. Guimaraes et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
The (un)targeted cancer kinome
Oleg Fedorov et al.
NATURE CHEMICAL BIOLOGY (2010)
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1
Valerie Hindie et al.
NATURE CHEMICAL BIOLOGY (2009)
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites
Ashley C. W. Pike et al.
EMBO JOURNAL (2008)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Ruthenium half-sandwich complexes bound to protein kinase Pim-1
JE Debreczeni et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Share Paper
